// App-Quantinova.ai

3245 : IL-15 superagonist/IL-15RSushi-Fc fusion complex (IL-15SA/IL-15RSu-Fc; ALT-803) markedly enhances specific subpopulations of NK and memory CD8+ T cells, and mediates potent anti-tumor activity of murine breast and colon carcinomas

Researchers

Presenter

  • Peter S. Kim

Principal Investigators

  • Anna R. Kwilas

  • Wenxin Xu

  • Sarah Alter

  • Emily K. Jeng

  • Hing C. Wong

  • Jeffrey Schlom

  • James W. Hodge

Medical Centers

  • National Human Genome Research Institute, National Institutes of Health, Bethesda, MD

  • Altor BioScience Corporation, Miramar, FL

Locations

  • United States

Companies

  • Altor BioScience Cor

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Colorectal Cancer

  • Bladder Cancer

  • Breast cancer

  • Glioblastoma

  • Solid malignancies

  • Multiple Myeloma

Biomarkers

  • Natural Killer cells

  • Cluster of Differentiation 44

  • Cluster of differentiation 8A

  • IL-2 receptor β

  • Interleukin-15

  • Natural killer group 2D

Drug/Treatment

  • Interleukin

  • Inbakicept

  • IL-15

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved